Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT05294965 |
| Other study ID # |
EKNZ 2022-00037 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
Early Phase 1
|
| First received |
|
| Last updated |
|
| Start date |
April 27, 2022 |
| Est. completion date |
March 6, 2023 |
Study information
| Verified date |
September 2023 |
| Source |
University Hospital, Basel, Switzerland |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
The purpose of the study is to asses brown adipose tissue activity in humans after
intravenous administration of the selective beta-2-adrenergic agonist fenoterol as compared
to the natural activator of brown adipose tissue, a mild cold stimulus.
Description:
The activation of brown adipose tissue in response to beta-2-adrenergic stimulation as
compared to cold exposure will be studied in an open-label, cross-over trial in healthy
volunteers with random sequence of the two study interventions a) and b):
1. A bolus of 25µg fenoterol will be slowly injected intravenously during 2-3 minutes
followed by a continuous infusion of fenoterol 1µg/min over 120 minutes. The total dose
of fenoterol per subject will thus be 145µg.
2. During 120 minutes participants will be exposed to a mild cold stimulus water using
cooling sleeves, covering the participant's waist, is gradually decrease body surface
temperature to 10 degrees or to the lowest tolerable temperature without shivering.
Energy expenditure will be measured during both interventions by indirect calorimetry and
brown adipose tissue activity will determined by 18F-FDG-PET/CT 30 min after injection of 75
MBq of 18F-FDG.